Article ; Online: Metabolic effects of an essential amino acid supplement in adolescents with PCOS and obesity.
2024 Volume 32, Issue 4, Page(s) 678–690
Abstract: Objective: Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, insulin resistance, and hepatic steatosis (HS). Because dietary essential amino acid (EAA) supplementation has been shown to decrease HS in various populations, this study' ...
| Abstract | Objective: Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, insulin resistance, and hepatic steatosis (HS). Because dietary essential amino acid (EAA) supplementation has been shown to decrease HS in various populations, this study's objective was to determine whether supplementation would decrease HS in PCOS. Methods: A randomized, double-blind, crossover, placebo-controlled trial was conducted in 21 adolescents with PCOS (BMI 37.3 ± 6.5 kg/m Results: Compared to placebo, EAA was associated with no difference in body weight (p = 0.673). Two markers of liver health improved: HS was lower (-0.8% absolute, -7.5% relative reduction, p = 0.013), as was plasma aspartate aminotransferase (AST) (-8%, p = 0.004). Plasma TG (-9%, p = 0.015) and VLDL-TG (-21%, p = 0.031) were reduced as well. VLDL-TG palmitate derived from lipogenesis was not different between the phases, nor was insulin sensitivity (p > 0.400 for both). Surprisingly, during the EAA phase, participants reported consuming fewer carbohydrates (p = 0.038) and total sugars (p = 0.046). Conclusions: Similar to studies in older adults, short-term EAA supplementation in adolescents resulted in significantly lower liver fat, AST, and plasma lipids and thus may prove to be an effective treatment in this population. Additional research is needed to elucidate the mechanisms for these effects. |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MeSH term(s) | Adolescent ; Female ; Humans ; Fatty Liver ; Hyperandrogenism/complications ; Insulin ; Insulin Resistance ; Lipoproteins, VLDL ; Obesity/complications ; Polycystic Ovary Syndrome/drug therapy ; Polycystic Ovary Syndrome/complications | ||||||||||
| Chemical Substances | Insulin ; Lipoproteins, VLDL | ||||||||||
| Language | English | ||||||||||
| Publishing date | 2024-03-04 | ||||||||||
| Publishing country | United States | ||||||||||
| Document type | Randomized Controlled Trial ; Journal Article | ||||||||||
| ZDB-ID | 2230457-5 | ||||||||||
| ISSN | 1930-739X ; 1071-7323 ; 1930-7381 | ||||||||||
| ISSN (online) | 1930-739X | ||||||||||
| ISSN | 1071-7323 ; 1930-7381 | ||||||||||
| DOI | 10.1002/oby.23988 | ||||||||||
| Shelf mark |
|
||||||||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 4061: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MG 87: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.